Full-Time

Senior Manager / Associate Director

External Manufacturing Operations

Immunome

Immunome

201-500 employees

Antibody-based therapeutic discovery and development

Compensation Overview

$152.5k - $185.8k/yr

Bothell, WA, USA

In Person

Category
Operations & Logistics (1)
Requirements
  • Bachelor’s or advanced degree in biotechnology, biology, chemistry, chemical engineering, or related field
  • Minimum of 10 years of biopharmaceutical industry experience, and direct responsibility overseeing third parties performing cGMP manufacturing
  • Ability to travel (domestic and international) up to 25%, with occasional evening and/or weekend commitment
Responsibilities
  • Serve as the Supplier Relationship Manager (SRM) for specified CDMOs and primary liaison between the CDMO and Immunome.
  • Collaborate closely with Legal to support the development and negotiation of service agreements, supply contracts, and statements of work across development and commercial phases.
  • Lead one or more Virtual Management Teams (VMTs) comprising Quality, Product Supply, Technical Development, and other cross-functional stakeholders as necessary.
  • Ensure Immunome’s project deliverables stay on track. Align priorities and key communications with the CDMO.
  • Conduct well-organized and documented project team meetings with CDMOs. Ensure CDMO progress is tracking to plan (e.g., campaign preparation, manufacturing operations, release activities, logistics, etc.). Proactively address delays to avoid impact on supply or regulatory milestones.
  • Develop a thorough understanding of Immunome’s drug product manufacturing processes. Support technical reviews of master and executed batch records, specifications, investigations, and change requests, as required.
  • Monitor CDMO performance through Key Performance Indicators (KPIs) and drive improvements aligned with Immunome’s expectations. Lead or participate in periodic Business Review Meetings.
  • Work closely with department management and finance team to provide timely progress updates. Ensure that unexpected cost variances are communicated quickly.
  • Maintain comprehensive knowledge of the CDMO’s systems, capabilities, capacities, requirements, and business practices.
  • Monitor spending against budget. Ensure CDMO invoicing is accurate and aligned with contractual terms.
  • Assist with technology transfers as needed, change implementation, and regulatory submission reviews.
  • Support Technical Operations sourcing efforts and the qualification of new CDMOs.
  • Support risk assessment development, and implementation of manufacturing network strategies.
  • This is an individual contributor role. Depending on the business needs and organizational considerations, this role may include staff supervisory responsibility as the product portfolio and manufacturing network expand.
Desired Qualifications
  • Experience with highly potent products is desired.
  • Experience with both clinical and commercial manufacturing is desired.
  • Experience with deviation investigations, change controls, and corrective actions is desirable.
  • Strong negotiation skills and be versed in general contractual terms is desirable.

Immunome identifies antibodies and their targets by studying the immune systems of patients who recover from diseases, to develop first-in-class therapeutics. Its platform analyzes immune responses to discover novel antibodies and their targets, which are then advanced through research and development in partnership with healthcare and medical research clients. The company’s products work by using antibodies discovered from patients’ immune systems to target diseases, potentially enabling new treatments across oncology and other areas. Immunome differentiates itself through a proprietary discovery platform that extracts clinically relevant antibodies from real patient immune responses, enabling collaborations and licensing deals rather than solely pursuing standalone drug sales. The goal is to bring new antibody therapies to patients by forming partnerships, licensing innovations, and eventually delivering approved therapies.

Company Size

201-500

Company Stage

IPO

Headquarters

Bothell, Washington

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Varegacestat NDA submitted April 2026; EMA filing expected by year-end 2026.
  • IM-1021 Phase 1 shows objective responses in B-cell lymphoma; data presentation expected 2026.
  • IM-1617 IND clearance enables Phase 1 initiation Q2 2026 with undisclosed solid tumor target.

What critics are saying

  • SpringWorks' nirogacestat dominates desmoid tumor guidelines, displacing varegacestat pre-launch.
  • FDA Complete Response Letter rejects varegacestat NDA due to CMO manufacturing deficiencies.
  • HC74 payload toxicity signals halt IM-1617, IM-1335, IM-1340 ADC programs entirely.

What makes Immunome unique

  • HC74 TOP1i payload enables higher clinical doses than competitor ADCs like MK-2140.
  • Proprietary discovery platform identified 30+ undisclosed solid tumor targets for ADC pipeline.
  • Roee Shahar's 20-year oncology commercialization experience accelerates varegacestat and pipeline launches.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Immunome who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Hybrid Work Options

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-10%
Yahoo Finance
Apr 4th, 2026
Immunome CSO sells $204K in shares ahead of Q2 2026 NDA submission

Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares on 2 April for $204,238, reducing his direct holdings by 30% to 22,000 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025 for financial diversification. The transaction comes as the clinical-stage biotechnology company approaches a significant milestone: its lead candidate varegacestat met the primary endpoint in a Phase 3 trial in December 2025, with an FDA submission planned for the second quarter of 2026. Immunome expects three additional investigational new drug applications and early data from IM-1021 across 2026. The company's stock has risen 250% over the past year, bringing its market capitalisation to $2.40 billion.

Yahoo Finance
Mar 6th, 2026
Immunome cuts 2025 net loss to $212M, files $156M shelf registration ahead of varegacestat NDA

Immunome has reported a reduced full-year net loss of $212.39 million for 2025 and filed a $156.03 million common stock shelf registration linked to an employee stock option plan offering. The biotechnology company also updated investors on progress in its oncology pipeline. The company plans to file a New Drug Application for varegacestat following positive Phase 3 data, with multiple solid tumour investigational new drug applications also in development. However, Immunome remains deeply unprofitable despite the narrower losses. The shelf registration raises concerns about potential equity dilution and ownership overhang. Fair value estimates from analysts vary widely, ranging from approximately $29 to over $215 per share, reflecting significant uncertainty around the company's prospects as it advances its high-risk oncology platform.

ChartMill
Jan 6th, 2026
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Immunome to present at 44th Annual J.P. Morgan Healthcare Conference. Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome's website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260106254447/en/

Business Wire
Dec 18th, 2025
Immunome Announces Pricing of Public Offering of Common Stock

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today a...

Business Wire
Feb 1st, 2025
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies,